Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by Scrip's global team, in this podcast version of Five Must-Know Things.
This episode covers insights for the business week ended 5 July 2024, including: US approval for Eli Lilly and Company’s Alzheimer's contender; the challenges and rewards of late-stage ADCs; Eisai Co., Ltd. regains control of ADC from Bristol Myers Squibb Company; RSV vaccine developers hit by declining expectations; and an interview with Amgen, Inc.’s Ian Thompson.
This and all our other podcasts are available on the Citeline channel on Apple Podcasts, Google Podcasts, SoundCloud, TuneIn and Spotify Podcasts, and via smart speakers if one of these platforms has been set up as your default podcast provider.
Stories mentioned in this episode:
(Also see "Lilly’s Kisunla Set To Give Leqembi A Run For Its Money In Early Alzheimer’s" - Scrip, 3 July, 2024.)
(Also see "Big Pharma Leads Development Of Novel Antibody-Drug Conjugates" - Scrip, 28 June, 2024.)
(Also see "Eisai Regains Full Control Of ADC Program After Bristol R&D Reprioritization" - Scrip, 1 July, 2024.)
(Also see "Moderna And GSK Hit By Declining RSV Vaccines Expectations" - Scrip, 28 June, 2024.)
(Also see "Amgen’s Ian Thompson On Payer Shifts, Obesity Opportunity And The Future Of Blockbusters" - Scrip, 28 June, 2024.)
